Use and Costs of Sentinel Lymph Node Biopsy in Non-Ulcerated T1b Melanoma: Analysis of a Population-Based Registry
- PMID: 33900501
- DOI: 10.1245/s10434-021-09998-6
Use and Costs of Sentinel Lymph Node Biopsy in Non-Ulcerated T1b Melanoma: Analysis of a Population-Based Registry
Abstract
Background: The utility of sentinel lymph node biopsy (SLNB) for non-ulcerated T1b melanoma is debated and associated costs are poorly characterized. Prior work using institutional registries may overestimate the incidence of nodal positivity in this population.
Objective: The aim of this study was to estimate the use of SLNB, positivity prevalence, and procedural costs in patients with non-ulcerated T1b melanoma using a population-based registry.
Methods: We identified patients with clinically node-negative, non-ulcerated melanoma 0.8-1.0 mm thick (T1b according to the 8th edition standard of the American Joint Committee on Cancer) in the Surveillance, Epidemiology, and End Results database from 2010 to 2016. The prevalence of SLNB procedures and positive sentinel nodes were calculated. Factors associated with SLNB and sentinel node positivity were assessed using logistic regression. Medicare reimbursement costs and patient out-of-pocket expenses for SLNB and wide local excision (WLE) versus WLE alone were estimated.
Results: Among 7245 included patients, 3835(53%) underwent SLNB, 156 (4.1%, 95% confidence interval 3.5-4.7) of whom had a positive SLNB. Younger age, >1 mitosis per mm2, female sex, and truncal tumor location were associated with higher odds of positivity. The estimated SLNB cost to identify one patient with stage III disease was $71,700 (range $54,648-$83,172). Out-of-pocket expenses for a Medicare patient were estimated to be $652 for a WLE and SLNB and $79 for a WLE alone.
Conclusions: In this population-based study, only 4% of selected non-ulcerated T1b patients had a positive SLNB, which is lower than prior reports. At the population level, SLNB is associated with high costs per prognostic information gained.
Keywords: Cost; Melanoma; Sentinel node biopsy.
Similar articles
-
Should Sentinel Lymph Node Biopsy Be Performed for All T1b Melanomas in the New 8th Edition American Joint Committee on Cancer Staging System?J Am Coll Surg. 2019 Apr;228(4):466-472. doi: 10.1016/j.jamcollsurg.2018.12.030. Epub 2019 Jan 17. J Am Coll Surg. 2019. PMID: 30660817
-
Sentinel Lymph Node Biopsy for T1b Melanoma: Balancing Prognostic Value and Cost.Ann Surg Oncol. 2020 Dec;27(13):5248-5256. doi: 10.1245/s10434-020-08558-8. Epub 2020 Jun 8. Ann Surg Oncol. 2020. PMID: 32514805 Free PMC article.
-
Differences in sentinel lymph node biopsy utilization in eligible melanoma patients treated with Mohs micrographic surgery or wide local excision: A population-based logistic regression model and survival analysis.J Am Acad Dermatol. 2023 Apr;88(4):848-855. doi: 10.1016/j.jaad.2022.11.004. Epub 2022 Nov 9. J Am Acad Dermatol. 2023. PMID: 36368376
-
Is there a relation between type of primary melanoma treatment and the development of intralymphatic metastasis? A review of the literature.Cancer Treat Rev. 2016 Apr;45:120-8. doi: 10.1016/j.ctrv.2016.02.007. Epub 2016 Mar 2. Cancer Treat Rev. 2016. PMID: 27015564 Review.
-
Sentinel lymph node biopsy for melanoma: indications and rationale.Cancer Control. 2009 Jul;16(3):234-9. doi: 10.1177/107327480901600305. Cancer Control. 2009. PMID: 19556963 Review.
Cited by
-
Association of sociodemographic characteristics with utilization of sentinel lymph node biopsy for American Joint Committee on Cancer 8th edition T1b cutaneous melanoma.Arch Dermatol Res. 2023 Nov;315(9):2697-2701. doi: 10.1007/s00403-023-02641-2. Epub 2023 May 30. Arch Dermatol Res. 2023. PMID: 37249586
References
-
- Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599–609. https://doi.org/10.1056/NEJMoa1310460 . - DOI - PubMed - PMC
-
- Clinical Practice Guidelines in Oncology: Cutaneous Melanoma. National comprehensive cancer network. 2019. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_... . Accessed 30 Sep 2019.
-
- Cordeiro E, Gervais MK, Shah PS, Look Hong NJ, Wright FC. Sentinel lymph node biopsy in thin cutaneous melanoma: a systematic review and meta-analysis. Ann Surg Oncol. 2016;23(13):4178–88. https://doi.org/10.1245/s10434-016-5137-z . - DOI - PubMed
-
- Han D, Yu D, Zhao X, et al. Sentinel node biopsy is indicated for thin melanomas ≥ 0. 76 mm. Ann Surg Oncol. 2012;19(11):3335–42. - DOI
-
- Han D, Zager JS, Shyr Y, et al. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. J Clin Oncol. 2013;31(35):4387–93. https://doi.org/10.1200/JCO.2013.50.1114 . - DOI - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical